Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $91.52 million
- Book Value:
- Revenue TTM:
- $34.22 million
- Operating Margin TTM:
- Gross Profit TTM:
- $28.74 million
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Co-Diagnostics Inc had its IPO on 2017-07-12 under the ticker symbol CODX.
The company operates in the Healthcare sector and Medical Devices industry. Co-Diagnostics Inc has a staff strength of 0 employees.
Shares of Co-Diagnostics Inc opened at $2.5 at the start of the last trading session i.e. 2023-03-19.
The stocks traded within a range of $2.44 - $2.77, and closed at $2.48.
This is a -16.22% slip from the previous day's closing price.
A total volume of 228,900 shares were traded at the close of the day’s session.
In the last one week, shares of Co-Diagnostics Inc have slipped by -13.89%.
Co-Diagnostics Inc's Key Ratios
Co-Diagnostics Inc has a market cap of $91.52 million, indicating a price to book ratio of 0.6346 and a price to sales ratio of 1.4524.
In the last 12-months Co-Diagnostics Inc’s revenue was $34.22 million with a gross profit of $28.74 million and an EBITDA of $-10308572. The EBITDA ratio measures Co-Diagnostics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Co-Diagnostics Inc’s operating margin was -33.88% while its return on assets stood at -5.12% with a return of equity of -11.44%.
In Q4, Co-Diagnostics Inc’s quarterly earnings growth was a positive 30.8% while revenue growth was a negative 93.1%.
Co-Diagnostics Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $0.42 per share while it has a forward price to earnings multiple of 16 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Co-Diagnostics Inc’s profitability.
Co-Diagnostics Inc stock is trading at a EV to sales ratio of 0.1837 and a EV to EBITDA ratio of -0.0407. Its price to sales ratio in the trailing 12-months stood at 1.4524.
Co-Diagnostics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $123.09 million
- Total Liabilities
- $3.87 million
- Operating Cash Flow
- Capital Expenditure
- $1.20 million
- Dividend Payout Ratio
Co-Diagnostics Inc ended 2023 with $123.09 million in total assets and $0 in total liabilities. Its intangible assets were valued at $123.09 million while shareholder equity stood at $114.52 million.
Co-Diagnostics Inc ended 2023 with $2.42 million in deferred long-term liabilities, $3.87 million in other current liabilities, 34754.00 in common stock, $39.93 in retained earnings and $0 in goodwill. Its cash balance stood at $22.97 million and cash and short-term investments were $81.26 million. The company’s total short-term debt was $297,209 while long-term debt stood at $0.
Co-Diagnostics Inc’s total current assets stands at $92.73 million while long-term investments were $0 and short-term investments were $58.29 million. Its net receivables were $5.32 million compared to accounts payable of $952297.00 and inventory worth $5.31 million.
In 2023, Co-Diagnostics Inc's operating cash flow was $-53306880.00 while its capital expenditure stood at $1.20 million.
Comparatively, Co-Diagnostics Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Co-Diagnostics Inc stock is currently trading at $2.48 per share. It touched a 52-week high of $7.13 and a 52-week low of $7.13. Analysts tracking the stock have a 12-month average target price of $11.67.
Its 50-day moving average was $2.9 and 200-day moving average was $3.78 The short ratio stood at 11.86 indicating a short percent outstanding of 0%.
Around 106.1% of the company’s stock are held by insiders while 1969.3% are held by institutions.
Frequently Asked Questions About Co-Diagnostics Inc
Similar Industry Stocks (Medical Devices)
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, tuberculosis, hepatitis B and C, human papilloma virus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. The company also provides tests that identify genetic traits in plant and animal genomes; and portable PCR device designed to bring PCR to patients in point-of-care and at-home settings. In addition, it intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.